Chlamydia Infection

Doxycycline, an antibiotic, is an orally active and broad-spectrum metalloproteinase (MMP) inhibitor. Doxycycline shows antibacterial activity and anti-cancer cell proliferation activity.

Doxycycline hyclate, an antibiotic, is an orally active and broad-spectrum metalloproteinase (MMP) inhibitor. Doxycycline hyclate shows antibacterial activity and anti-cancer cell proliferation activity. Doxycycline hyclate can be used to construct gene expression regulation models.

Doxycycline hydrochloride, an antibiotic, is an orally active and broad-spectrum metalloproteinase (MMP) inhibitor. Doxycycline hydrochloride shows antibacterial activity and anti-cancer cell proliferation activity. Doxycycline hydrochloride can be used to construct gene expression regulation models.

Ceftriaxone (Ro 13-9904 free acid) is a broad spectrum β-lactam third-generation cephalosporin antibiotic, which has good antibacterial activity against a variety of gram-negative and positive bacteria. Ceftriaxone is a covalent inhibitor of GSK3β with IC₅₀ value of 0.78 μM. Ceftriaxone is an inhibitor of Aurora B. Ceftriaxone has anti-inflammatory, antitumor and antioxidant activities. Ceftriaxone can be used in the study of bacterial infections and meningitis.

Ceftriaxone sodium salt (Ro 13-9904) is a broad spectrum β-lactam third-generation cephalosporin antibiotic, which has good antibacterial activity against a variety of gram-negative and positive bacteria. Ceftriaxone sodium salt is a covalent inhibitor of GSK3β with IC₅₀ value of 0.78 μM. Ceftriaxone sodium salt is an inhibitor of Aurora B. Ceftriaxone sodium salt has anti-inflammatory, antitumor and antioxidant activities. Ceftriaxone sodium salt can be used in the study of bacterial infections and meningitis.

Doxycycline monohydrate is an orally active highly lipophilic, tissue-permeable MMP inhibitor with broad-spectrum antibacterial activity. Doxycycline monohydrate is also a semi-synthetic antibiotic with chelating properties, which blocks bacterial protein synthesis and inhibits extracellular matrix degradation through interactions with zinc and calcium atoms. Doxycycline monohydrate also inhibits mitochondrial biogenesis, translation, and the expression of respiratory chain proteins. Doxycycline monohydrate induces apoptosis, inhibits autophagy and EMT, downregulates stem cell markers, and activates the PI3K-AKT pathway, thereby effectively inhibiting the viability and proliferation of cancer cells such as breast cancer cells. Doxycycline monohydrate also promotes the survival and self-renewal of embryonic stem cells and neural stem cells, and reduces the frequency of medium changes in culture. Doxycycline monohydrate has been applied in studies related to breast cancer, prostate cancer, bladder cancer, and other cancers.

Rifalazil (KRM-1648; ABI-1648), a rifamycin derivative, inhibits the bacterial DNA-dependent RNA polymerase and kills bacterial cells by blocking off the β-subunit in RNA polymerase. Rifalazil (KRM-1648; ABI-1648) is an antibiotic, exhibits high potency against mycobacteria, gram-positive bacteria, Helicobacter pylori, C. pneumoniae and C. trachomatis with MIC values from 0.00025 to 0.0025 μg/ml. Rifalazil (KRM-1648; ABI-1648) has the potential for the treatment of Chlamydia infection, Clostridium difficile associated diarrhea (CDAD), and tuberculosis (TB).

Ceftriaxone sodium hydrate (Ro 13-9904 sodium hydrate) is a broad spectrum β-lactam third-generation cephalosporin antibiotic, which has good antibacterial activity against a variety of gram-negative and positive bacteria. Ceftriaxone sodium hydrate is a covalent inhibitor of GSK3β with IC₅₀ value of 0.78 μM. Ceftriaxone sodium hydrate is an inhibitor of Aurora B. Ceftriaxone sodium hydrate has anti-inflammatory, antitumor and antioxidant activities. Ceftriaxone sodium hydrate can be used in the study of bacterial infections and meningitis.

Erythromycin-13C2 is a macrolide antibiotic that can be used to treat respiratory infections, skin infections, and chlamydia infections.

Doxycycline calcium is an orally active highly lipophilic, tissue-permeable MMP inhibitor with broad-spectrum antibacterial activity. Doxycycline calcium is also a semi-synthetic antibiotic with chelating properties, which blocks bacterial protein synthesis and inhibits extracellular matrix degradation through interactions with zinc and calcium atoms. Doxycycline calcium also inhibits mitochondrial biogenesis, translation, and the expression of respiratory chain proteins. Doxycycline calcium induces apoptosis, inhibits autophagy and EMT, downregulates stem cell markers, and activates the PI3K-AKT pathway, thereby effectively inhibiting the viability and proliferation of cancer cells such as breast cancer cells. Doxycycline calcium also promotes the survival and self-renewal of embryonic stem cells and neural stem cells, and reduces the frequency of medium changes in culture. Doxycycline calcium has been applied in studies related to breast cancer, prostate cancer, bladder cancer, and other cancers.

JO146 is an anti-chlamydial agent, Antibacterial agent, and CtHtrA serine protease inhibitor, with an IC₅₀ of 21.86 μM against CtHtrA serine protease. JO146 alters the morphology of chlamydial cells, reduces inclusion vacuoles, decreases the number of infectious progeny, and eliminates viable Chlamydia trachomatis under stress or conditions that reverse persistent infection. JO146 shows no activity against Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus aureus, but exhibits bactericidal activity against Helicobacter pylori. JO146 can be used in research related to Chlamydia trachomatis infection, chlamydial infection in cattle and sheep, and Helicobacter pylori infection.

Rifalazil (Standard) is the analytical standard of Rifalazil. This product is intended for research and analytical applications. Rifalazil (KRM-1648; ABI-1648), a rifamycin derivative, inhibits the bacterial DNA-dependent RNA polymerase and kills bacterial cells by blocking off the β-subunit in RNA polymerase[1]. Rifalazil (KRM-1648; ABI-1648) is an antibiotic, exhibits high potency against mycobacteria, gram-positive bacteria, Helicobacter pylori, C. pneumoniae and C. trachomatis with MIC values from 0.00025 to 0.0025 μg/ml[3]. Rifalazil (KRM-1648; ABI-1648) has the potential for the treatment of Chlamydia infection, Clostridium difficile associated diarrhea (CDAD), and tuberculosis (TB)[2].

Danofloxacin-d₃ is deuterium labeled Danofloxacin. Danofloxacin is an orally active quinolone antibiotic. Danofloxacin targets bacterial DNA gyrase and inhibits bacterial DNA replication, transcription and growth. Danofloxacin can be used for various bacterial infections caused by Escherichia coli, Mycoplasma and other pathogens.

Danofloxacin-d3-1 is deuterium labeled Danofloxacin. Danofloxacin is an orally active quinolone antibiotic. Danofloxacin targets bacterial DNA gyrase and inhibits bacterial DNA replication, transcription and growth. Danofloxacin can be used for various bacterial infections caused by Escherichia coli, Mycoplasma and other pathogens.

Doxycycline fosfatex is an orally active highly lipophilic, tissue-permeable MMP inhibitor with broad-spectrum antibacterial activity. Doxycycline fosfatex is also a semi-synthetic antibiotic with chelating properties, which blocks bacterial protein synthesis and inhibits extracellular matrix degradation through interactions with zinc and calcium atoms. Doxycycline fosfatex also inhibits mitochondrial biogenesis, translation, and the expression of respiratory chain proteins. Doxycycline fosfatex induces apoptosis, inhibits autophagy and EMT, downregulates stem cell markers, and activates the PI3K-AKT pathway, thereby effectively inhibiting the viability and proliferation of cancer cells such as breast cancer cells. Doxycycline fosfatex also promotes the survival and self-renewal of embryonic stem cells and neural stem cells, and reduces the frequency of medium changes in culture. Doxycycline fosfatex has been applied in studies related to breast cancer, prostate cancer, bladder cancer, and other cancers.

CppA-IN-1 is a CppA inhibitor specific to Chlamydia trachomatis, which inhibits the growth of Chlamydia trachomatis. CppA-IN-1 shows no activity against recombinant CppA in vitro. CppA-IN-1 can be used in studies related to Chlamydia trachomatis infection.

Danofloxacin (Standard) is the analytical standard of Danofloxacin. This product is intended for research and analytical applications. Danofloxacin is an orally active quinolone antibiotic. Danofloxacin targets bacterial DNA gyrase and inhibits bacterial DNA replication, transcription and growth. Danofloxacin can be used for various bacterial infections caused by Escherichia coli, Mycoplasma and other pathogens.

Dirithromycin (Standard) is the analytical standard of Dirithromycin. This product is intended for research and analytical applications. Dirithromycin (LY237216), a derivative of Erythromycin, is a potent and orally active semi-synthetic macrolide antibiotic. Dirithromycin is active against gram-positive bacteria, Legionella spp., Helicobacter pylori, and Chlamydia trachomatis.